Sims N, Levesque J
Curr Osteoporos Rep. 2024; 22(1):80-95.
PMID: 38198032
PMC: 10912291.
DOI: 10.1007/s11914-023-00837-z.
Soler M, Abaurrea A, Azcoaga P, Araujo A, Caffarel M
J Immunother Cancer. 2023; 11(11).
PMID: 37945321
PMC: 10649711.
DOI: 10.1136/jitc-2023-007530.
Polak K, Tamagno I, Parameswaran N, Smigiel J, Ricky Chan E, Yuan X
Mol Cancer Res. 2023; 21(9):975-990.
PMID: 37310811
PMC: 10527478.
DOI: 10.1158/1541-7786.MCR-22-0715.
Sasaki N, Hirano K, Shichi Y, Gomi F, Yoshimura H, Matsushita A
Cancers (Basel). 2022; 14(9).
PMID: 35565185
PMC: 9100112.
DOI: 10.3390/cancers14092055.
Bailey J, Hang H, Boudreau A, Elks C
Int J Mol Sci. 2022; 23(9).
PMID: 35563078
PMC: 9104719.
DOI: 10.3390/ijms23094689.
Stimulation of Osteoclast Formation by Oncostatin M and the Role of WNT16 as a Negative Feedback Regulator.
de Souza P, Henning P, Lerner U
Int J Mol Sci. 2022; 23(6).
PMID: 35328707
PMC: 8953253.
DOI: 10.3390/ijms23063287.
Murine Oncostatin M Has Opposing Effects on the Proliferation of OP9 Bone Marrow Stromal Cells and NIH/3T3 Fibroblasts Signaling through the OSMR.
Jakob L, Muller T, Rassner M, Kleinfelder H, Veratti P, Mitschke J
Int J Mol Sci. 2021; 22(21).
PMID: 34769079
PMC: 8584221.
DOI: 10.3390/ijms222111649.
WNT16 is Robustly Increased by Oncostatin M in Mouse Calvarial Osteoblasts and Acts as a Negative Feedback Regulator of Osteoclast Formation Induced by Oncostatin M.
Henning P, Moverare-Skrtic S, Westerlund A, de Souza P, Floriano-Marcelino T, Nilsson K
J Inflamm Res. 2021; 14:4723-4741.
PMID: 34566421
PMC: 8457865.
DOI: 10.2147/JIR.S323435.
Endosomes as Signaling Platforms for IL-6 Family Cytokine Receptors.
Schmidt-Arras D, Rose-John S
Front Cell Dev Biol. 2021; 9:688314.
PMID: 34141712
PMC: 8204807.
DOI: 10.3389/fcell.2021.688314.
Changes in the phosphorylation of nucleotide metabolism‑associated proteins by leukemia inhibitory factor in mouse embryonic stem cells.
Song H, Kim H, Kim S, Lim H, Kim H, Han M
Mol Med Rep. 2021; 23(6).
PMID: 33846773
PMC: 8060798.
DOI: 10.3892/mmr.2021.12070.
Balancing STAT Activity as a Therapeutic Strategy.
Polak K, Chernosky N, Smigiel J, Tamagno I, Jackson M
Cancers (Basel). 2019; 11(11).
PMID: 31684144
PMC: 6895889.
DOI: 10.3390/cancers11111716.
Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor.
Persson E, Souza P, Floriano-Marcelino T, Conaway H, Henning P, Lerner U
Front Immunol. 2019; 10:1164.
PMID: 31191537
PMC: 6547810.
DOI: 10.3389/fimmu.2019.01164.
Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines.
West N
Front Immunol. 2019; 10:1093.
PMID: 31156640
PMC: 6529849.
DOI: 10.3389/fimmu.2019.01093.
Oncostatin M induces RIG-I and MDA5 expression and enhances the double-stranded RNA response in fibroblasts.
Hergovits S, Mais C, Haan C, Costa-Pereira A, Hermanns H
J Cell Mol Med. 2017; 21(11):3087-3099.
PMID: 28560754
PMC: 5661242.
DOI: 10.1111/jcmm.13221.
Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.
Junk D, Bryson B, Smigiel J, Parameswaran N, Bartel C, Jackson M
Oncogene. 2017; 36(28):4001-4013.
PMID: 28288136
PMC: 5509502.
DOI: 10.1038/onc.2017.33.
STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.
Bryson B, Junk D, Cipriano R, Jackson M
Cell Cycle. 2016; 16(4):319-334.
PMID: 27892764
PMC: 5324753.
DOI: 10.1080/15384101.2016.1259037.
Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.
Heise R, Amann P, Ensslen S, Marquardt Y, Czaja K, Joussen S
PLoS One. 2016; 11(1):e0146325.
PMID: 26735690
PMC: 4703378.
DOI: 10.1371/journal.pone.0146325.
Regulation of IL-17A responses in human airway smooth muscle cells by Oncostatin M.
Kwofie K, Scott M, Rodrigues R, Guerette J, Radford K, Nair P
Respir Res. 2015; 16:14.
PMID: 25849622
PMC: 4332894.
DOI: 10.1186/s12931-014-0164-4.
The enigmatic cytokine oncostatin m and roles in disease.
Richards C
ISRN Inflamm. 2014; 2013:512103.
PMID: 24381786
PMC: 3870656.
DOI: 10.1155/2013/512103.
Oncostatin M and TLR-4 ligand synergize to induce MCP-1, IL-6, and VEGF in human aortic adventitial fibroblasts and smooth muscle cells.
Schnittker D, Kwofie K, Ashkar A, Trigatti B, Richards C
Mediators Inflamm. 2013; 2013:317503.
PMID: 24307759
PMC: 3836373.
DOI: 10.1155/2013/317503.